» Articles » PMID: 22069110

Improved Synthesis and Mutagenicity of Oligonucleotides Containing 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine

Overview
Journal Chemistry
Specialty Chemistry
Date 2011 Nov 10
PMID 22069110
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

5-Formylcytosine (fC or (5-CHO)dC) and 5-carboxylcytosine (caC or (5-COOH)dC) have recently been identified as constituents of mammalian DNA. The nucleosides are formed from 5-methylcytosine (mC or (5-Me)dC) via 5-hydroxymethylcytosine (hmC or (5-HOMe)dC) and are possible intermediates of an active DNA demethylation process. Here we show efficient syntheses of phosphoramidites which enable the synthesis of DNA strands containing these cytosine modifications based on Pd(0)-catalyzed functionalization of 5-iododeoxycytidine. The first crystal structure of fC reveals the existence of an intramolecular H-bond between the exocyclic amine and the formyl group, which controls the conformation of the formyl substituent. Using a newly designed in vitro mutagenicity assay we show that fC and caC are only marginally mutagenic, which is a prerequisite for the bases to function as epigenetic control units.

Citing Articles

Unrepaired base excision repair intermediates in template DNA strands trigger replication fork collapse and PARP inhibitor sensitivity.

Serrano-Benitez A, Wells S, Drummond-Clarke L, Russo L, Thomas J, Leal G EMBO J. 2023; 42(18):e113190.

PMID: 37492888 PMC: 10505916. DOI: 10.15252/embj.2022113190.


Active DNA demethylation-The epigenetic gatekeeper of development, immunity, and cancer.

Prasad R, Yen T, Bellacosa A Adv Genet (Hoboken). 2023; 2(1):e10033.

PMID: 36618446 PMC: 9744510. DOI: 10.1002/ggn2.10033.


Chemical and enzymatic modifications of 5-methylcytosine at the intersection of DNA damage, repair, and epigenetic reprogramming.

Baljinnyam T, Sowers M, Hsu C, Conrad J, Herring J, Hackfeld L PLoS One. 2022; 17(8):e0273509.

PMID: 36037209 PMC: 9423628. DOI: 10.1371/journal.pone.0273509.


Diagnostic and Prognostic Power of Active DNA Demethylation Pathway Intermediates in Acute Myelogenous Leukemia and Myelodysplastic Syndromes.

Skalska-Bugala A, Starczak M, Szukalski L, Gawronski M, Siomek-Gorecka A, Szpotan J Cells. 2022; 11(5).

PMID: 35269510 PMC: 8909098. DOI: 10.3390/cells11050888.


The urinary excretion of epigenetically modified DNA as a marker of pediatric ALL status and chemotherapy response.

Rozalski R, Gackowski D, Skalska-Bugala A, Starczak M, Siomek-Gorecka A, Zarakowska E Sci Rep. 2021; 11(1):21345.

PMID: 34725426 PMC: 8560782. DOI: 10.1038/s41598-021-00880-9.